Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof
US-2016083361-A1 · Mar 24, 2016 · US
Compounds for inducing anti-tumor immunity and methods thereof
US9957506B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9957506-B2 |
| Application number | US-201415024215-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 25, 2014 |
| Priority date | Sep 25, 2013 |
| Publication date | May 1, 2018 |
| Grant date | May 1, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for enhancing or inducing an anti-tumor immune response in a subject, comprising administering to the subject an effective amount of a direct inhibitor of IRE1α for enhancing or inducing an anti-tumor immune response in the subject, wherein the effective amount of the direct inhibitor IRE1α increases antigen presentation in antigen presenting cells, wherein the tumor is a solid tumor, and wherein the solid tumor is from an ovarian cancer, epithelial cancer, germ cell cancer, a stromal tumor. 2. The method of claim 1 , wherein the epithelial cancer is a carcinoma or an adenocarcinoma. 3. The method of claim 1 , wherein the direct inhibitor of IRE-1α is an IRE-1α-specific antibody or a small molecule inhibitor of IRE-1α. 4. The method of claim 1 , wherein the direct inhibitor of IRE-1α is administered systemically or at tumor locations in the subject. 5. The method of claim 1 , wherein the direct inhibitor of IRE-1α targets tumor-associated dendritic cells (tDCs). 6. The method of claim 1 , wherein the direct inhibitor of IRE-1α is administered in combination with a second cancer therapeutic agent. 7. The method of claim 6 , wherein the second cancer therapeutic agent is a chemotherapeutic agent. 8. The method of claim 1 , wherein the treatment induces extended survival of the subject. 9. The method of claim 1 , wherein the anti-tumor immune response is mediated by adaptive immune cells. 10. The method of claim 9 , wherein the adaptive immune cells comprise T cells.
Assignees
Inventors
Classifications
Protein-serine/threonine kinases (2.7.11) · CPC title
- C12N15/113Primary
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title
Double-stranded nucleic acids or oligonucleotides · CPC title
Combination therapy · CPC title
Antisense · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9957506B2 cover?
- Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
- Who is the assignee on this patent?
- Univ Cornell
- What technology area does this patent fall under?
- Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).